Article

Segment 13: Final Thoughts on Clinical Diagnostic Tests

The panelists share their thoughts on the future of diagnostic tests and what changes they are looking forward to, such as developing better systems to integrate clinical information with molecular data and increased FDA oversight.

The panelists share their thoughts on the future of diagnostic tests and what changes they are looking forward to.

Bryan Loy, MD, MBA, is optimistic about the future, but recognizes that the issues of accountability and FDA governance are the least of the concerns in the area of diagnostic testing.

Daniel F. Hayes, MD, believes having more consistent regulations by making things harder will actually make things easier to get new markers out.

Francisco J. Esteva, MD, PhD, said better systems need to be developed to integrate the clinical information with molecular data to ensure patients get the appropriate care.

John L. Fox, MD, MHA, is also looking forward to increased FDA oversight, although he added that it will still remain to be seen whether the medical community can ensure the tests are used appropriately so the right patients receive the right treatment.

Related Videos
dr ian neeland
Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network
Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council
Phaedra Corso, PhD, associate vice president for research at Indiana University
Julie Patterson, PharmD, PhD
Nancy Dreyer, MPH, PhD, FISE, chief scientific advisor to Picnic Health
Seth Berkowitz, MD, MPH, associate professor of medicine, University of North Carolina at Chapel Hill
Inma Hernandez, PharmD, PhD, professor at the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo